Cannabinoids and the placenta: Receptors, signaling and outcomes
Placenta · 2023-04 · 135 · 51-61
DOI: 10.1016/j.placenta.2023.03.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Placenta, 2023-04. Verfasst von Abbey C E Rokeby und 2 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Cannabinoids, Cannabidiol. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, NICHD, CIHR IHDCYH.
Abstract (Originalsprache)
Cannabis use during pregnancy is increasing. The improvement of pregnancy-related symptoms including morning sickness and management of mood and stress are among the most reported reasons for its use. Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the most abundant cannabinoids found within the cannabis flower. The concentration of these components has drastically increased in the past 20 years. Additionally, many edibles contain only one cannabinoid and are marketed to achieve a specific goal, meaning there are an increasing number of pregnancies that are exposed to isolated cannabinoids. Both Δ9-THC and CBD cross the placenta and can impact the fetus directly, but the receptors through which cannabinoids act are also expressed throughout the placenta, suggesting that the effects of in-utero cannabinoid exposure may include indirect effects from the placenta. In-utero cannabis research focuses on short and long-term fetal health and development; however, these studies include little to no placenta analysis. Prenatal cannabinoid exposure is linked to small for gestational age and fetal growth-restricted babies. Compromised placental development is also associated with fetal growth restriction and the few studies (clinical and animal models) that included placental analysis, identify changes in placental vasculature and function in these cannabinoid-exposed pregnancies. In vitro studies further support cannabinoid impact on cell function in the different populations that comprise the placenta. In this article, we aim to summarize how phytocannabinoids can impact placental development and function. Specifically, the cannabinoids and their actions at the different receptors are described, with receptor localization throughout the human and murine placenta discussed. Findings from studies that included placental analysis and how cannabinoid signaling may modulate critical developmental processing including cell proliferation, angiogenesis and migration are described. Considering the current research, prenatal cannabinoid exposure may significantly impact placental development, and, as such, identifying windows of placental vulnerability for each cannabinoid will be critical to elucidate the etiology of fetal outcome studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Department of Obstetrics and Gynaecology, Queen's University, Kingston, ON, Canada.
- Department of Obstetrics and Gynaecology, Queen's University, Kingston, ON, Canada; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. Electronic address: drcn@queensu.ca.
Förderung
- NICHD NIH HHS
- NICHD
- CIHR IHDCYH
Zitieren
APA
Rokeby, A. C. E., Natale, B. V., & Natale, D. R. C. (2023). Cannabinoids and the placenta: Receptors, signaling and outcomes. Placenta, 135, 51-61. https://doi.org/10.1016/j.placenta.2023.03.002
Vancouver
Rokeby ACE, Natale BV, Natale DRC. Cannabinoids and the placenta: Receptors, signaling and outcomes. Placenta. 2023;135:51-61. doi:10.1016/j.placenta.2023.03.002
BibTeX
@article{Rokeby2023,
author = {Rokeby, Abbey C E and Natale, Bryony V and Natale, David R C},
title = {Cannabinoids and the placenta: Receptors, signaling and outcomes},
journal = {Placenta},
year = {2023},
volume = {135},
pages = {51--61},
doi = {10.1016/j.placenta.2023.03.002}
}
EUVIMED